ArticleBMC nephrology2026
A retrospective study on the current status of palliative care for patients who have chronic kidney failure in Japan: analysis of big data of the national insurance system.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnder the current Japanese health insurance system, patients with malignancy and severe heart failure are provided coverage for palliative care. Moreover, little is known about the comorbidities in the chronic kidney failure (CKF) patients. The National Database of Health Insurance Claims and Special Health Checkups of Japan (NDB), which includes data on most Japanese insurance practices contains the digital data not only comorbidities, but also related to palliative care, i.e. advance care planning (home care, use of emergency room, intensive care, life-prolonging treatment) and opioid use. Thus, we aimed to investigate the status of palliative care for patients with CKF in Japan by analysis of NDB data.
methodsWe assessed data on deaths in 2019 with CKF listed in the injury/illness record of the NDB. Practice codes related to age groups in five-year increments, gender, disease titles, use of opioids within one month before death, use of the emergency services, invasive and life-prolonging treatment, home care, and place of death were investigated.
resultData of a total of 70269 patients (5.1% of all deaths in 2019) were included. The comorbidities included malignancy (25.6%) and heart failure (25.5%). Oxycodone accounted for 68.3% of the oral opioids, whereas morphine accounted for 59.4% of the injectable opioids. The proportion of codes related to emergency care did not differ significantly between age groups. The proportion of codes related to lifesaving measures decreased linearly with age. Although the proportion of codes for home care and end-of-life care at home increased exponentially with age, only 17.2% of patients aged 90 years and older received home-based end-of-life care.
conclusionAt least 5% of all deaths occurred in individuals diagnosed with CKF. Nearly half of them also had malignancy or heart failure, suggesting that palliative care was accessible even within the current National Health Insurance system. Morphine was the most frequently used injectable opioid in the month preceding death. Among elderly patients, emergency medical care involved little attempted resuscitation. Nevertheless, home-based end-of-life care accounted for only about 20% even among the oldest old. These findings suggested the need to further promote palliative care services for CKF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.